AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Clinical/Scientific Notes
June 25, 2020
Open Access Letter to the Editor

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

Johan Virhammar, MD, PhD, Eva Kumlien, MD, PhD, David Fällmar, MD, PhD https://orcid.org/0000-0001-5615-2036, Robert Frithiof, MD, PhD, Sven Jackmann, MD, Mattias K. Sköld, MD, PhD, Mohamed Kadir, MD, Jens Frick, MD, Jonas Lindeberg, MD, Henrik Olivero-Reinius, MD, PhD, Mats Ryttlefors, MD, PhD, Janet L. Cunningham, MD, PhD, Johan Wikström, MD, PhD, Anna Grabowska, MD, Kåre Bondeson, MD, PhD, Jonas Bergquist, MD, PhD, Henrik Zetterberg, MD, PhD, and Elham Rostami, MD, PhDAuthors Info & Affiliations
September 8, 2020 issue
95 (10) 445-449
https://doi.org/10.1212/WNL.0000000000010250
Letters to the Editor
full text

Abstract

Here, we report a case of COVID-19–related acute necrotizing encephalopathy where SARS-CoV-2 RNA was found in CSF 19 days after symptom onset after testing negative twice. Although monocytes and protein levels in CSF were only marginally increased, and our patient never experienced a hyperinflammatory state, her neurologic function deteriorated into coma. MRI of the brain showed pathologic signal symmetrically in central thalami, subinsular regions, medial temporal lobes, and brain stem. Extremely high concentrations of the neuronal injury markers neurofilament light and tau, as well as an astrocytic activation marker, glial fibrillary acidic protein, were measured in CSF. Neuronal rescue proteins and other pathways were elevated in the in-depth proteomics analysis. The patient received IV immunoglobulins and plasma exchange. Her neurologic status improved, and she was extubated 4 weeks after symptom onset. This case report highlights the neurotropism of SARS-CoV-2 in selected patients and emphasizes the importance of repeated lumbar punctures and CSF analyses in patients with suspected COVID-19 and neurologic symptoms.

Case report

In early April 2020, a 55-year-old, previously healthy, woman was admitted to the emergency department at a rural hospital due to fever and myalgia. A CT scan of the thorax showed pulmonary ground-glass opacities and consolidations, and PCR analysis of nasopharyngeal swab specimens confirmed the diagnosis of COVID-19. She had been caring for her husband and 90-year-old mother who both had cough and high fever and also tested positive for SARS-CoV-2 RNA.
After returning home the following day, she became lethargic and had difficulty managing the stairs to her bedroom (day 7 after symptom onset, timeline illustrated in the figure). Later that night, she was found unresponsive in bed. At readmission, her temperature was 37.6°C. She was hemodynamically stable and had no respiratory problems. She was stuporous and had multifocal myoclonus. A CT scan of the brain revealed symmetrical hypodensities in the thalami. A lumbar puncture was performed on day 9 that, in the absence of pleocytosis, did not raise suspicion of CNS infection. PCR tests for herpes simplex virus (HSV) and varicella zoster virus (VZV) were negative. However, signs of blood-brain barrier disruption were noted. On day 11, the patient's neurologic status deteriorated, and she was intubated and transferred to the intensive care unit (ICU). A new CT scan showed low-attenuating areas in the thalami and midbrain, and acute necrotizing encephalitis (ANE) related to her SARS-CoV-2 infection was suspected. Treatment with IV immunoglobulin (IVIG) was initiated in addition to acyclovir.
Figure Timeline from symptoms to discharge and MRI scans illustrating anatomic location and alterations over time
(A) Timeline from symptom debut showing the neurologic status of the patient and the start and duration of the immunotherapies. The graph additionally illustrates the dynamics of inflammatory markers in plasma and CSF. The first and only positive PCR for SARS-CoV-2 in CSF was detected after 3 weeks indicated by red arrows. IVIG, IV immunoglobulin, PLEX, plasma exchange, GCS, Glasgow Coma Scale. (B) The top and middle rows show images from the first MRI scan at day 12, and the bottom row from the follow-up 1 week later. T2 turbo spin echo (B.a) and FLAIR (B.b) show symmetrically increased signal intensity in subinsular regions (surrounding the claustrum) and thalami (red arrow). The same areas had bright signal in trace images from diffusion-weighted images (b 1,000), indicating cytotoxic edema (B.c). Increased signal was also present on FLAIR images in the brain stem (asterisk, B.h) with suggested involvement of trigeminal nerves (without contrast enhancement, B.d). The olfactory tract had normal appearance (not shown). T1-weighted images show distinct signal decrease on the initial scan (B.e), with partial normalization on follow-up and small delineated malacias in the thalami (B.j). There was faint contrast enhancement initially (B.f), more evident on follow-up (boxes; B.k). Initial FLAIR images showed clear symmetrical involvement of medial temporal lobes, hippocampi, and cerebral peduncles (asterisks, B.g), as well as the pons (B.d, B.h). On follow-up, there was substantial decrease of signal changes in hippocampi and mesencephalon (B.l, B.m). Susceptibility-weighted images showed multiple small foci of presumed petechial hemorrhage in central thalami and subinsular regions (red arrows; B.i, B.n).
On day 12, the patient was transferred to the ICU at a tertiary referral hospital. Her neurologic symptoms had by then worsened, with impaired brain stem reflexes. MRI of the brain showed symmetrical pathologic signal patterns on all sequences, compatible with ANE (figure). In CSF from a second lumbar puncture on day 12, the cell count was normal, IgG concentration slightly increased, and albumin concentration had normalized. No specific autoantibodies could be detected, and once again, PCR for HSV, VZV, and SARS-CoV-2 in CSF was negative.
However, CSF biomarkers for neuronal injury including neurofilament light (NfL) and tau were markedly increased. Glial fibrillary acidic protein (GFAp), a biomarker for astrocytic activation and neuroinflammation, was also highly elevated. In addition, interleukin 6 (IL6) in CSF was somewhat increased. At this time, the systemic inflammatory markers (CRP and WBC) were normal to slightly elevated (figure). Neuronal rescue protein levels were significantly increased in the proteomics analysis of CSF. Other proteins that changed during the disease course included lipid transporters, enzyme cofactors, cell surface receptor ligands, apolipoproteins, and innate immune system complement factors, possibly reflecting the dynamics of the underlying pathology. Proteomics data are available from Dryad, https://doi.org/10.5061/dryad.xwdbrv1bb.
On day 14, a scant improvement was noted with an increased level of consciousness and normalization of brain stem reflexes. Continuous EEG monitoring showed generalized showed slow waves without epileptiform activity. A second MRI revealed partial regression of the signal changes in the brain stem and medial temporal lobes, while contrast enhancements in central thalami and subinsular regions were more pronounced (figure). Venography showed patent veins, and no hypoperfusion was detected in this patient (image available at Dryad, https://doi.org/10.5061/dryad.xwdbrv1bb).
Of interest, in the third CSF sampling, rRT-PCR for SARS-CoV-2 targeting the N gene was positive at a cycle threshold value of 34.29. At this low concentration, the finding was not reproducible using a commercial PCR assay (Abbott RealTime SARS-CoV-2; Abbott Molecular, Wiesbaden, Germany). Biomarkers of neuronal injury, NfL and tau, had further increased, whereas GFAp and IL6 had decreased. CSF protein levels were increased, and oligoclonal bands were now detected in CSF.
ANE carries a poor prognosis, and there is no specific therapy because the etiology is unknown. However, because CSF IgG levels were increased, immunotherapy with plasma exchange (PLEX) was started at day 20. We decided against continued treatment with IVIG based on the reported high thromboembolic incidence in patients with COVID-19. The patient received newly collected replacement donor plasma in the hope that it contained SARS-CoV-2 antibodies.
Gradually, the patient's neurologic condition improved, and on day 32, she could nod, spontaneously, move her legs, and point to a photograph of her children. GFAp had normalized, but NfL and tau remained strongly increased (figure). She was extubated on day 35 and discharged to rehabilitation.

Discussion

This case report demonstrates 2 important aspects of SARS-CoV-2: first, that the virus may have significant neurotropism, and second, that normal CSF cell counts and initial negative SARS-CoV-2 RNA PCR results in CSF do not exclude CNS engagement. This case also underscores the value of repeated CSF testing when CNS COVID-19 is suspected.
The first report of a patient with COVID-19 and ANE was published in March 2020.1 In that case, the presence of virus in CSF was not examined. The case had similar radiologic features as reported here: symmetric thalamic lesions, hemorrhagic components, and involvement of medial temporal lobes and subinsular regions. The latter 2 components are not commonly described features of ANE and could possibly reflect a COVID-19–specific aspect of the pathophysiology. An earlier report by Moriguchi et al.2 described a patient with unilateral involvement of the medial temporal lobe where the virus was detected in the CSF.
ANE is recognized as a distinct entity with a rapid onset of neurologic symptoms, most often secondary to a viral infection such as influenza and herpes viruses. MRI findings include bilateral signal changes and necrosis symmetrically in central thalami and sometimes with hemorrhagic components and/or involvement of the anterior brain stem. Despite its association with viral infection, ANE is not usually considered an inflammatory encephalitis. In fact, the absence of CSF pleocytosis is one of the diagnostic criteria for ANE.3 It has been suggested that an intense surge of proinflammatory cytokines causes focal damage to the blood-brain barrier, with edema and necrosis as secondary effects. This cytokine storm or hyperinflammatory state is described in subgroups of patients with viral infections, including COVID-19. In our patient, however, markers for systemic inflammation were only mildly elevated. Immunotherapy in this case led to clinical improvement. This encouraging result, although congruent with a potentially inhibited or halted inflammatory process, should be interpreted with caution.
Neurotropism of coronaviruses and an association with demyelinating lesions have been demonstrated in both human and animal studies.4 Recently, SARS-CoV-2 was detected in brain tissue at autopsy, and viral infection of the neurons was confirmed.5 A possible route of entry could be the trigeminal and olfactory nerves.6 Infiltration through the olfactory system could explain the increased FLAIR signal in the medial temporal lobe.7 The signal changes in the brainstem and thalamus may represent a central infiltration through the trigeminal system. The bilateral alterations in the claustrum are very unusual; the findings might be a consequence of neuronal retrograde dissemination as the claustrum has a central position in the limbic system.
High levels of IgG in CSF and oligoclonal bands indicate an ongoing inflammatory process, and demyelination and axonal injury were confirmed by extremely high levels of NfL and tau.
The virus was detected only after repeated CSF samplings. The single positive test result in CSF coincides with elevated damage markers and could either be a sign of increased virus load/RNA over time, release of virus from damaged nerve cells, or possibly a false-positive test result. The negative test result with the commercial test kit could either be the low sensitivity of the test kit or simply missed by chance. Further studies are needed to confirm this finding and elucidate the route of entry of SARS-CoV-2 into the CNS and the immunologic response in COVID-19–related ANE. The diagnostic and prognostic values of biomarkers for axonal injury and inflammation, MRI, and treatment options with immunotherapy should be key elements in future studies.

Acknowledgment

The authors thank Niklas Edner at Consultant in Clinical Microbiology at Public Health Agency of Sweden for insightful comments and Ganna Shevchenko for support in the proteomics analysis.

Appendix Authors

References

1.
Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020;296:E119–E120.
Crossref
PubMed
Google Scholar
2.
Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020;94:55–58.
Crossref
PubMed
Google Scholar
3.
Mizuguchi M. Acute necrotizing encephalopathy of childhood: a novel form of acute encephalopathy prevalent in Japan and Taiwan. Brain Dev 1997;19:81–92.
Crossref
PubMed
Google Scholar
4.
Murray RS, Cai GY, Hoel K, Zhang JY, Soike KF, Cabirac GF. Coronavirus infects and causes demyelination in primate central nervous system. Virology 1992;188:274–284.
Crossref
PubMed
Google Scholar
5.
Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2). J Med Virol 2020;92:699–702.
Crossref
PubMed
Google Scholar
6.
Lau KK, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004;10:342–344.
Crossref
PubMed
Google Scholar
7.
Perlman S, Jacobsen G, Afifi A. Spread of a neurotropic murine coronavirus into the CNS via the trigeminal and olfactory nerves. Virology 1989;170:556–560.
Crossref
PubMed
Google Scholar
Letters to the Editor
11 September 2020
Reader response: Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid
Jennifer A. Frontera, Neurologist | NYU Langone Hospitals
Ariane Lewis, Neurologist | NYU Langone Hospitals
Shadi Yaghi, Neurologist | NYU Langone Hospitals
Adarsh Bhimraj, Internal Medicine- Infectious Diseases | Cleveland Clinic

Virhammar et. al.1 present a case of acute necrotizing encephalopathy (ANE) in a patient with COVID-19 diagnosed by nasopharyngeal swab PCR1. SARS-CoV-2-PCR testing on two CSF specimens performed on days 9 and 12 after symptom onset were negative, while a third CSF specimen tested positive at a cycle threshold (Ct) of 34.29 at 21 days. While interesting, these results do not indicate that SARS-COV-2 is neurotropic. First, most experts consider Ct counts >40 to represent a negative test and counts >34 may not represent meaningful disease.2 Since PCR testing can amplify contaminants, this result may be a false positive, particularly with negative initial CSF testing. Second, since ANE is typically a post-infectious disease, a biologically plausible causal link with a weakly positive CSF PCR at 21 days is not established. Third, a large series of patients with COVID-19 who had neurologic symptoms found SARS-CoV-2 PCR was negative in CSF in 100% of patients.3 Although one study reportedly detected SARS-CoV-2 in a brain autopsy,4 no immunohistochemistry studies were performed and rough endoplasmic reticulum may be mistaken for virions. Larger brain autopsy series using immunohistochemistry have not detected primary viral CNS invasion.5 Direct neurotropism of SARS-CoV-2 has yet to be definitively established.

Disclosure

The authors report no relevant disclosures. Contact [email protected] for full disclosures.

References

  1. Virhammar J, Kumlien E, Fallmar D, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology 2020,95:445–449.
  2. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. Clin Infect Dis 2020 Epub May 21.
  3. Neumann B, Schmidbauer ML, Dimitriadis K, et al. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. J Neurol Sci 2020;418:117090.
  4. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020;92:699–702.
  5. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological Features of Covid-19. N Engl J Med 2020;383:989–992.
10 September 2020
Reader response: Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid
Calixto Machado, Senior Professor and Researcher in Neurology, Corresponding Fellow of the American Academy of Neurology | Institute of Neurology and Neurosurgery (Havana, Cuba)
Philip A. DeFina, Neuroscientist | International Brain Research Foundation

Virhammar et al.1 reported a Covid-19 patient who developed an acute necrotizing encephalopathy (ANE) in whom SARS-CoV-2 RNA was detected in the CSF. The authors remarked that, first, SARS-CoV-2 shows a significant neurotropism, and, second, to consider repetitive CSF samples for PCR assessment.1

Several routes used by the neurotropic virus to reach CNS have been described: transneural and hematogenous pathways.2 Following infection of superior airways, SARS-CoV-2 passes through the epithelium and gains access to the bloodstream, leading to a cytokine storm, which might be an important etiologic mechanism to the ANE.3

The olfactory nerve connects the nasal cavity directly with the CNS and might therefore be a fast and easy shortcut for SARS-CoV-2 into the CNS.2,3  Proposed mechanisms are either infection of olfactory receptor neurons (ORNs) themselves or diffusion through channels formed by olfactory ensheathing cells. Subsequent virus spread through the CNS could occur through multiple mechanisms, including trans‐synaptic transport and microfusion. ORNs’ axons pass through the CSF of the subarachnoid space terminating on mitral and tuft cells in the olfactory bulbs. This might explain the presence of SARS-CoV-2 in the CSF.2,4,5

We agree with the authors1 that that repetitive CSF samples should be considered for PCR assessment in Covid-19 patients.

Disclosure

The authors report no relevant disclosures. Contact [email protected] for full disclosures.

References

  1. Virhammar J, Kumlien E, Fallmar D, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology 2020,95:445–449.
  2. Machado-Curbelo C. Severe Covid-19 cases: Is respiratory distress partially explained by central nervous system involvement? MEDICC Review 2020;22:38–39.
  3. Li Z, Liu T, Yang N, et al. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front Med 2020 Epub May 4.
  4. van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol 2015;235:277–287.
  5. Mori I, Nishiyama Y, Yokochi T, Kimura Y. Olfactory transmission of neurotropic viruses. J Neurovirol 2005;11:129–137.

Information & Authors

Information

Published In

Neurology®
Volume 95 • Number 10 • September 8, 2020
Pages: 445-449
PubMed: 32586897

Copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Publication History

Received: May 14, 2020
Accepted: June 19, 2020
Published online: June 25, 2020
Published in print: September 8, 2020

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

Supported by the Swedish Research Council and Open Medicine Foundation. HZ and ER are Wallenberg Academy Fellows.

Authors

Affiliations & Disclosures

Johan Virhammar, MD, PhD*
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Swedish Society for Medical Research, (2) Hanna Eklund's foundation for neurological research, (3) Major Gösta Lind's foundation, (4) Thuréus foundation for geriatric research
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Eva Kumlien, MD, PhD*
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David Fällmar, MD, PhD https://orcid.org/0000-0001-5615-2036
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Post doc position (current)
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Robert Frithiof, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Swedish Research Council grant no 2014-02569 and 2014- 07606
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sven Jackmann, MD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
1 Smärta i klinisk praxis, Annica Rhodin (red), Studentlitteratur, 2019
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mattias K. Sköld, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate Editor for Frontiers in Neurology, Neurotrauma section. Editor in Cheif Marten Risling. No economic compensation.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mohamed Kadir, MD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jens Frick, MD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jonas Lindeberg, MD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Henrik Olivero-Reinius, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mats Ryttlefors, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Janet L. Cunningham, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Johan Wikström, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Swedish Cancer Research Foundation: 19 0476 Pj, PI, 2020-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anna Grabowska, MD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Kåre Bondeson, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jonas Bergquist, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate Editor Royal Chemical Society Analytical Methods 2015-2021
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Henrik Zetterberg, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
HZ has served at advisory boards for Denali, Roche Diagnostics, Samumed, CogRx and Wave (not related to submitted work).
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor Molecular and Cellular Neuroscience, Editor Scandinavian Journal of Clinical and Laboratory Investigation, Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (not related to submitted work).
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Swedish State Support for Clinical Research (#ALFGBG- 720931) and (2) the Knut and Alice Wallenberg Foundation (Wallenberg Scholar).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Elham Rostami, MD, PhD
From the Department of Neuroscience (J.V., E.K., S.J.), Neurology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (D.F., J.W., A.G.), Radiology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences (R.F., H.D.P.D.O.-R.), Anaesthesia and Intensive Care, Uppsala University, Uppsala, Sweden; Department of Neuroscience (M.K.S., H.D.P.D.O.-R., E.R.), Neurosurgery, Uppsala University, Uppsala, Sweden; Department of Internal Medicine (M.K., J.L.), Nyköping Hospital, Nyköping, Sweden; Department of Radiology (J.F.), Nyköping Hospital, Nyköping, Sweden; Department of Neuroscience (J.L.C.), Psychiatry, Uppsala University, Uppsala, Sweden; Department of Medical Sciences (K.B.), Uppsala University, Uppsala, Sweden; Department of Chemistry—BMC (J.B.), Analytical Chemistry and Neurochemistry, Uppsala University, Uppsala, Sweden; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; and Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate editor of Frontiers in neurology.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Rostami [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
*
These authors contributed equally to the manuscript.
Written informed consent for this case report was obtained from the patient's guardian.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Roopa Naik,
    • Sreekant Avula,
    • Sujith K Palleti,
    • Jyotsna Gummadi,
    • Rajarajeshwari Ramachandran,
    • Deepak Chandramohan,
    • Gagandeep Dhillon,
    • Angad S Gill,
    • Kapil Paiwal,
    • Bushra Shaik,
    • Malavika Balachandran,
    • Bhumika Patel,
    • Simhachalam Gurugubelli,
    • Abhishek Kumar Mariswamy Arun Kumar,
    • Athmananda Nanjundappa,
    • Mahita Bellamkonda,
    • Kanika Rathi,
    • Pavana Lalithya Sakhamuri,
    • Mahmoud Nassar,
    • Atul Bali,
    From Emergence to Endemicity: A Comprehensive Review of COVID-19, Cureus, (2023).https://doi.org/10.7759/cureus.48046
    Crossref
    • Priyal .,
    • Vineet Sehgal,
    • Saniya Kapila,
    • Rishabh Taneja,
    • Prachi Mehmi,
    • Nihal Gulati,
    Review of Neurological Manifestations of SARS-CoV-2, Cureus, (2023).https://doi.org/10.7759/cureus.38194
    Crossref
    • Shaghayegh Karami,
    • Fattaneh Khalaj,
    • Houman Sotoudeh,
    • Zohreh Tajabadi,
    • Ramin Shahidi,
    • Mohammad Amin Habibi,
    • Mahsa Shirforoush Sattari,
    • Amir Azimi,
    • Seyed Ali Forouzannia,
    • Romina Rafiei,
    • Hamid Reihani,
    • Reza Nemati,
    • Soraya Teimori,
    • Amirmohammad Khalaji,
    • Vida Sarmadi,
    • Ali Dadjou,
    Acute Necrotizing Encephalopathy in Adult Patients With COVID-19: A Systematic Review of Case Reports and Case Series, Journal of Clinical Neurology, 19, 6, (597), (2023).https://doi.org/10.3988/jcn.2022.0431
    Crossref
    • Carolline Soares Motta,
    • Silvia Torices,
    • Barbara Gomes da Rosa,
    • Anne Caroline Marcos,
    • Liandra Alvarez-Rosa,
    • Michele Siqueira,
    • Thaidy Moreno-Rodriguez,
    • Aline da Rocha Matos,
    • Braulia Costa Caetano,
    • Jessica Santa Cruz de Carvalho Martins,
    • Luis Gladulich,
    • Erick Loiola,
    • Olivia R. M. Bagshaw,
    • Jeffrey A. Stuart,
    • Marilda M. Siqueira,
    • Joice Stipursky,
    • Michal Toborek,
    • Daniel Adesse,
    Human Brain Microvascular Endothelial Cells Exposure to SARS-CoV-2 Leads to Inflammatory Activation through NF-κB Non-Canonical Pathway and Mitochondrial Remodeling, Viruses, 15, 3, (745), (2023).https://doi.org/10.3390/v15030745
    Crossref
    • Paolo Manganotti,
    • Gabriele Garascia,
    • Giovanni Furlanis,
    • Alex Buoite Stella,
    Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review, Frontiers in Neuroscience, 17, (2023).https://doi.org/10.3389/fnins.2023.1159929
    Crossref
    • Xia Lin,
    • Ying Wang,
    • Xiaoying Li,
    • Mohnad Abdalla,
    • Fan Zhang,
    • Chunhua Dong,
    • Weifeng Lu,
    • Xia Liu,
    • Jian Zhang,
    • Kang Ma,
    • Xiang Ma,
    • Qin Jiang,
    Acute necrotizing encephalopathy in children with COVID-19: a retrospective study of 12 cases, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1184864
    Crossref
    • Ock-Bin Im,
    • Min-Jee Kim,
    • Mi-Sun Yum,
    • Won Kyoung Jhang,
    Coronavirus disease 2019-associated acute necrotizing encephalopathy in a 9-year-old boy, Pediatric Emergency Medicine Journal, 10, 4, (142-148), (2023).https://doi.org/10.22470/pemj.2023.00724
    Crossref
    • Vanessa W. Lee,
    • Kai Qian Kam,
    • Ahmad R. Mohamed,
    • Husna Musa,
    • Poorani Anandakrishnan,
    • Qingtang Shen,
    • Alexander F. Palazzo,
    • Russell C. Dale,
    • Ming Lim,
    • Terrence Thomas,
    Defining the Clinicoradiologic Syndrome of SARS-CoV-2 Acute Necrotizing Encephalopathy, Neurology Neuroimmunology & Neuroinflammation, 11, 1, (2023)./doi/10.1212/NXI.0000000000200186
    Abstract
    • Majid Reza Farrokhi,
    • Farideh Iravanpour,
    • Negar Nejabat,
    Development of Acute Transverse Myelitis following COVID-19 Infection: A Review on the Potential Pathways, European Neurology, 86, 3, (209-216), (2023).https://doi.org/10.1159/000529927
    Crossref
    • Rachel L Brown,
    • Laura Benjamin,
    • Michael P Lunn,
    • Tehmina Bharucha,
    • Michael S Zandi,
    • Chandrashekar Hoskote,
    • Patricia McNamara,
    • Hadi Manji,
    Pathophysiology, diagnosis, and management of neuroinflammation in covid-19, BMJ, (e073923), (2023).https://doi.org/10.1136/bmj-2022-073923
    Crossref
  11. See more

View Options

View options

Full Text

View Full Text

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Save for later Item saved, go to cart
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF